期刊
JOURNAL OF IMMUNOLOGICAL METHODS
卷 407, 期 -, 页码 82-89出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jim.2014.03.026
关键词
NKT cells; aAPCs; CD1d
资金
- NIH/NCI [K01 CA131487, R21 CA162273, R21 CA162277]
Introduction: NKT cells comprise a rare, but important subset of T cells which account for similar to 0.2% of the total circulating T cell population. NKT cells are known to have anti-tumor functions and rapidly produce high levels of cytokines following activation. Several clinical trials have sought to exploit the effector functions of NKT cells. While some studies have shown promise, NKT cells are approximately 50% lower in cancer patients compared to healthy donors of the same age and gender, thus limiting their therapeutic efficacy. These studies indicate that baseline levels of activation should be assessed before initiating an NKT cell based immunotherapeutic strategy. Aim: The goal of this study was to develop a sensitive method to rapidly assess NKT cell function. Methods: We utilized artificial antigen presenting cells in combination with qPCR in order to determine NKT cell function in peripheral blood mononuclear cells from healthy donors and breast cancer patients. Results: We found that NKT cell activation can be detected by qPCR, but not by ELISA, in healthy donors as well as in breast cancer patients following four hour stimulation. Conclusion: This method utilizing CD1d-expressing aAPCs will enhance our knowledge of NKT cell biology and could potentially be used as a novel tool in adoptive immunotherapeutic strategies. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据